Vigene Biosciences, an award-winning specialist in plasmid and viral vector development and manufacturing, has appointed Molly McGlaughlin as chief operation officer. 
 
McGlaughlin, a long-term Biologics Contract Development and Manufacturing Organization (CDMO) industry senior executive, comes to us with 27 years of experiences in biologics manufacturing and development. She has served on the executive management teams of BioLexis, BioVectra, EirGenix, Selexis S.A., Natrix Separations, Cytovance Biologics, Avecia Biotechnology (now Fuji Diosynth) and Patheon. McGlaughlin is also a Colonel in the US Army Reserves with experience as a joint information warfare planner and commanding at the Brigade level.  She earned her BS from Norwich University and master’s degrees from Capella University (ABD), US Army War College, and University of Massachusetts Boston. 
 
“Ms. McGlaughlin is an experienced leader in the CDMO field,” said Dr. Zairen Sun, president and CEO of Vigene Biosciences. “Ms. McGlaughlin has led the significant growth of CDMOs to execute and deliver projects on time while upholding stringent quality and compliance standards. I am confident that the addition of Ms. McGlaughlin will be complementary to our rapidly growing organization and will greatly enhance Vigene’s capabilities to meet the increasing demand for viral vector and plasmid manufacturing.”
 
“I am very excited to be part of this fast-growing organization; and am confident about the prospect of enhancing Vigene’s leadership position in the global viral vector and plasmid development and manufacturing field,” McGlaughlin commented.